The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.

French pharma major Sanofi (Euronext: SAN) and investment firm Cathay Capital have launched a $275 million fund that will invest in clinical-stage drugs in China. The Sanofi-Cathay Pharmaceutical ...

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

It’s not HBO, it’s Max — but the new standalone logo for Warner Bros. Discovery‘s streamer now certainly looks like HBO’s at a glance. The Max streaming service has quietly launched a ...

The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY).Designed for patients aged 12 and older ...